Literature DB >> 28280273

A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML.

L M Kats1,2, S J Vervoort1, R Cole1, A J Rogers1, G P Gregory1,2,3, E Vidacs1, J Li2,4, R Nagaraja5, K E Yen5, R W Johnstone1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28280273     DOI： 10.1038/leu.2017.84

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   12.883


× No keyword cloud information.
  15 in total

1.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

2.  Transcriptional analysis of quiescent and proliferating CD34+ human hemopoietic cells from normal and chronic myeloid leukemia sources.

Authors:  Susan M Graham; J Keith Vass; Tessa L Holyoake; Gerard J Graham
Journal:  Stem Cells       Date:  2007-08-23       Impact factor: 6.277

3.  A stem cell molecular signature.

Authors:  Natalia B Ivanova; John T Dimos; Christoph Schaniel; Jason A Hackney; Kateri A Moore; Ihor R Lemischka
Journal:  Science       Date:  2002-09-12       Impact factor: 47.728

4.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.

Authors:  Lenny Dang; David W White; Stefan Gross; Bryson D Bennett; Mark A Bittinger; Edward M Driggers; Valeria R Fantin; Hyun Gyung Jang; Shengfang Jin; Marie C Keenan; Kevin M Marks; Robert M Prins; Patrick S Ward; Katharine E Yen; Linda M Liau; Joshua D Rabinowitz; Lewis C Cantley; Craig B Thompson; Matthew G Vander Heiden; Shinsan M Su
Journal:  Nature       Date:  2009-12-10       Impact factor: 49.962

5.  Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.

Authors:  Peppi Koivunen; Sungwoo Lee; Christopher G Duncan; Giselle Lopez; Gang Lu; Shakti Ramkissoon; Julie A Losman; Päivi Joensuu; Ulrich Bergmann; Stefan Gross; Jeremy Travins; Samuel Weiss; Ryan Looper; Keith L Ligon; Roel G W Verhaak; Hai Yan; William G Kaelin
Journal:  Nature       Date:  2012-02-15       Impact factor: 49.962

6.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.

Authors:  Maria E Figueroa; Omar Abdel-Wahab; Chao Lu; Patrick S Ward; Jay Patel; Alan Shih; Yushan Li; Neha Bhagwat; Aparna Vasanthakumar; Hugo F Fernandez; Martin S Tallman; Zhuoxin Sun; Kristy Wolniak; Justine K Peeters; Wei Liu; Sung E Choe; Valeria R Fantin; Elisabeth Paietta; Bob Löwenberg; Jonathan D Licht; Lucy A Godley; Ruud Delwel; Peter J M Valk; Craig B Thompson; Ross L Levine; Ari Melnick
Journal:  Cancer Cell       Date:  2010-12-09       Impact factor: 38.585

7.  The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

Authors:  Patrick S Ward; Jay Patel; David R Wise; Omar Abdel-Wahab; Bryson D Bennett; Hilary A Coller; Justin R Cross; Valeria R Fantin; Cyrus V Hedvat; Alexander E Perl; Joshua D Rabinowitz; Martin Carroll; Shinsan M Su; Kim A Sharp; Ross L Levine; Craig B Thompson
Journal:  Cancer Cell       Date:  2010-02-18       Impact factor: 38.585

8.  Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2.

Authors:  Satoshi Inoue; Wanda Y Li; Alan Tseng; Isabel Beerman; Andrew J Elia; Sean C Bendall; François Lemonnier; Ken J Kron; David W Cescon; Zhenyue Hao; Evan F Lind; Naoya Takayama; Aline C Planello; Shu Yi Shen; Alan H Shih; Dana M Larsen; Qinxi Li; Bryan E Snow; Andrew Wakeham; Jillian Haight; Chiara Gorrini; Christian Bassi; Kelsie L Thu; Kiichi Murakami; Alisha R Elford; Takeshi Ueda; Kimberly Straley; Katharine E Yen; Gerry Melino; Luisa Cimmino; Iannis Aifantis; Ross L Levine; Daniel D De Carvalho; Mathieu Lupien; Derrick J Rossi; Garry P Nolan; Rob A Cairns; Tak W Mak
Journal:  Cancer Cell       Date:  2016-07-14       Impact factor: 31.743

Review 9.  IDH2 inhibition in AML: Finally progress?

Authors:  Eytan M Stein
Journal:  Best Pract Res Clin Haematol       Date:  2015-10-19       Impact factor: 3.670

10.  Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition.

Authors:  Chong Chen; Yu Liu; Chao Lu; Justin R Cross; John P Morris; Aditya S Shroff; Patrick S Ward; James E Bradner; Craig Thompson; Scott W Lowe
Journal:  Genes Dev       Date:  2013-09-15       Impact factor: 11.361
View more
  9 in total

Review 1.  Cholangiocarcinoma - evolving concepts and therapeutic strategies.

Authors:  Sumera Rizvi; Shahid A Khan; Christopher L Hallemeier; Robin K Kelley; Gregory J Gores
Journal:  Nat Rev Clin Oncol       Date:  2017-10-10       Impact factor: 66.675

Review 2.  Oncometabolites in renal cancer.

Authors:  Cissy Yong; Grant D Stewart; Christian Frezza
Journal:  Nat Rev Nephrol       Date:  2019-10-21       Impact factor: 28.314

3.  Biochemical and Epigenetic Insights into L-2-Hydroxyglutarate, a Potential Therapeutic Target in Renal Cancer.

Authors:  Sandeep Shelar; Eun-Hee Shim; Garrett J Brinkley; Anirban Kundu; Francesca Carobbio; Tyler Poston; Jubilee Tan; Vishwas Parekh; Daniel Benson; David K Crossman; Phillip J Buckhaults; Dinesh Rakheja; Richard Kirkman; Yusuke Sato; Seishi Ogawa; Shilpa Dutta; Sadanandan E Velu; Ethan Emberley; Alison Pan; Jason Chen; Tony Huang; Devin Absher; Anja Becker; Conrad Kunick; Sunil Sudarshan
Journal:  Clin Cancer Res       Date:  2018-08-14       Impact factor: 12.531

4.  Allosteric inhibitor remotely modulates the conformation of the orthestric pockets in mutant IDH2/R140Q.

Authors:  Jiao Chen; Jie Yang; Xianqiang Sun; Zhongming Wang; Xiaolan Cheng; Wuguang Lu; Xueting Cai; Chunping Hu; Xu Shen; Peng Cao
Journal:  Sci Rep       Date:  2017-11-28       Impact factor: 4.996

Review 5.  Non-genetic heterogeneity, altered cell fate and differentiation therapy.

Authors:  Alexander C Lewis; Lev M Kats
Journal:  EMBO Mol Med       Date:  2021-02-08       Impact factor: 12.137

6.  Oncometabolite L-2-hydroxyglurate directly induces vasculogenic mimicry through PHLDB2 in renal cell carcinoma.

Authors:  Huan Wang; Liya Wang; Qiming Zheng; Zeyi Lu; Yuanlei Chen; Danyang Shen; Dingwei Xue; Minxiao Jiang; Lifeng Ding; Jie Zhang; Haiyang Wu; Liqun Xia; Jun Qian; Gonghui Li; Jieyang Lu
Journal:  Int J Cancer       Date:  2021-01-15       Impact factor: 7.396

7.  Preclinical efficacy against acute myeloid leukaemia of SH1573, a novel mutant IDH2 inhibitor approved for clinical trials in China.

Authors:  Zhiqiang Wang; Zhibo Zhang; Yong Li; Li Sun; Dezhen Peng; Danyu Du; Xian Zhang; Luwei Han; Liwen Zhao; Ligong Lu; Hongzhi Du; Shengtao Yuan; Meixiao Zhan
Journal:  Acta Pharm Sin B       Date:  2021-03-09       Impact factor: 11.413

8.  CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells.

Authors:  Christine Surka; Liqing Jin; Nathan Mbong; Chin-Chun Lu; In Sock Jang; Emily Rychak; Derek Mendy; Thomas Clayton; Elizabeth Tindall; Christy Hsu; Celia Fontanillo; Eileen Tran; Adrian Contreras; Stanley W K Ng; Mary Matyskiela; Kai Wang; Philip Chamberlain; Brian Cathers; James Carmichael; Joshua Hansen; Jean C Y Wang; Mark D Minden; Jinhong Fan; Daniel W Pierce; Michael Pourdehnad; Mark Rolfe; Antonia Lopez-Girona; John E Dick; Gang Lu
Journal:  Blood       Date:  2021-02-04       Impact factor: 25.476

9.  Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma.

Authors:  Bingqi Ma; Huijuan Meng; Ye Tian; Yingying Wang; Tianqiang Song; Ti Zhang; Qiang Wu; Yunlong Cui; Huikai Li; Wei Zhang; Qiang Li
Journal:  BMC Cancer       Date:  2020-04-15       Impact factor: 4.638
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.